Atlas Trials

Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19

Clinical trial NCT05122182 · TERMINATED

Trial details

NCT number
NCT05122182
Sponsor
University of Sydney
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
COVID-19SARS-CoV2 Infection
Start date
2022-01-07
Primary completion
2022-08-15
Enrollment
49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.